Physicians have long used beta interferon drugs to treat multiple sclerosis (MS), but these drugs only help about half
of patients. Now, samples and data from the MURDOCK
MS Study are helping researchers to better understand the difference between those who respond to beta-interferon treatment and those who do not. That could lead to alternative treatment options for people living with MS.
The MURDOCK MS Study team published a paper about interferon-beta resistance in the journal Nature Neuroscience on Nov. 7, 2016. Researchers used genetic data from MS study participants to compare the disease pathways in patients who respond to interferon-beta treatments with those who do not. This led to the discovery of biomarkers that indicate what triggered the difference in the two disease types. The research continues, with an additional publication coming soon.
The biological samples and data provided by MURDOCK MS participants are now fueling the research of Discovery MS, a new research initiative located within the David H. Murdock Research Institute at the North Carolina Research Campus. Simon Gregory, Ph.D., leads Discovery MS. The MURDOCK Primary Progressive Multiple Sclerosis Study continues follow-up visits and serial sampling.
The journal publication was announced during the MURDOCK MS Study enrollment closeout celebration and launch of Discovery MS at the North Carolina Research Campus.